Maze Therapeutics, Inc. (MAZE) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the May Therapeutics Horizon MZE829 Top Line Data conference call. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touchtone phone. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Ms. Amy Backworld. Please go ahead. Good morning, all, and thank you for joining us. Today, we will be discussing this morning's announcement of positive tap line data from the Phase II Horizon Trial of MZE829, an oral small molecule dual mechanism APOL1 inhibitor for the treatment of broad APOL1-mediated kidney disease, or AMKD. Please note this conference call is being recorded. Before we start, I would like to remind you that today's conference call will include forward-looking statements. Such statements represent management's judgment and intention as of today and involve assumptions, risks, and uncertainties. MAIS undertakes no obligation to update or revise any forward-looking statements. Please refer to MAIS's filings with the SEC, which are available from the SEC or on the MAIS website for information concerning the risk factors that could affect the company. Joining us on today's call are Jason Coloma, CEO of Maize, and Harold Bernstein, President of R&D and Chief Medical Officer at Maize. Today's presentation will begin with introductory remarks from Jason, followed by Harold, who will review the trial design and the data announced today. Jason will then provide closing remarks before we are joined by Misbah Tahir, Chief Fi...